CL2023002223A1 - Inhibidores de cdk2 y métodos de uso de los mismos - Google Patents
Inhibidores de cdk2 y métodos de uso de los mismosInfo
- Publication number
- CL2023002223A1 CL2023002223A1 CL2023002223A CL2023002223A CL2023002223A1 CL 2023002223 A1 CL2023002223 A1 CL 2023002223A1 CL 2023002223 A CL2023002223 A CL 2023002223A CL 2023002223 A CL2023002223 A CL 2023002223A CL 2023002223 A1 CL2023002223 A1 CL 2023002223A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- cdk2
- cdk2 inhibitors
- inhibitors
- disorders
- Prior art date
Links
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 title abstract 3
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
La presente divulgación proporciona compuestos, composiciones de los mismos y métodos de uso de los mismos para la inhibición de CDK2, y el tratamiento de enfermedades y trastornos relacionados con CDK2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163143360P | 2021-01-29 | 2021-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023002223A1 true CL2023002223A1 (es) | 2023-12-29 |
Family
ID=82654899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023002223A CL2023002223A1 (es) | 2021-01-29 | 2023-07-27 | Inhibidores de cdk2 y métodos de uso de los mismos |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230109076A1 (es) |
| EP (1) | EP4284365A1 (es) |
| JP (1) | JP2024505261A (es) |
| KR (1) | KR20230142745A (es) |
| CN (1) | CN117177744A (es) |
| AU (1) | AU2022214618A1 (es) |
| BR (1) | BR112023015210A2 (es) |
| CA (1) | CA3208618A1 (es) |
| CL (1) | CL2023002223A1 (es) |
| CO (1) | CO2023010023A2 (es) |
| CR (1) | CR20230362A (es) |
| DO (1) | DOP2023000145A (es) |
| EC (1) | ECSP23057264A (es) |
| IL (1) | IL304728A (es) |
| PE (1) | PE20240050A1 (es) |
| TW (1) | TW202239402A (es) |
| WO (1) | WO2022165513A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024026483A2 (en) * | 2022-07-28 | 2024-02-01 | Cedilla Therapeutics, Inc. | Cdk2 inhibitors and methods of using the same |
| WO2024026481A2 (en) * | 2022-07-29 | 2024-02-01 | Cedilla Therapeutics, Inc. | Cdk2 inhibitors and methods of using the same |
| WO2024026479A2 (en) * | 2022-07-29 | 2024-02-01 | Cedilla Therapeutics, Inc. | Cdk2 inhibitors and methods of using the same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2771327A1 (en) * | 2009-09-04 | 2011-03-10 | Glaxosmithkline Llc | Chemical compounds |
| UY33199A (es) * | 2010-01-26 | 2011-08-31 | Boehringer Ingelheim Int | 5-alquinil-pirimidinas. |
| JP2021516229A (ja) * | 2018-02-28 | 2021-07-01 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 低親和性ポリ（ａｄ−リボース）ポリメラーゼ１依存性細胞毒性剤 |
-
2022
- 2022-01-28 CA CA3208618A patent/CA3208618A1/en active Pending
- 2022-01-28 WO PCT/US2022/070409 patent/WO2022165513A1/en active Application Filing
- 2022-01-28 CN CN202280024871.XA patent/CN117177744A/zh active Pending
- 2022-01-28 PE PE2023002221A patent/PE20240050A1/es unknown
- 2022-01-28 CR CR20230362A patent/CR20230362A/es unknown
- 2022-01-28 EP EP22746916.0A patent/EP4284365A1/en active Pending
- 2022-01-28 KR KR1020237029169A patent/KR20230142745A/ko unknown
- 2022-01-28 BR BR112023015210A patent/BR112023015210A2/pt unknown
- 2022-01-28 US US17/649,269 patent/US20230109076A1/en active Pending
- 2022-01-28 JP JP2023546536A patent/JP2024505261A/ja active Pending
- 2022-01-28 AU AU2022214618A patent/AU2022214618A1/en active Pending
- 2022-01-28 TW TW111104194A patent/TW202239402A/zh unknown
-
2023
- 2023-07-25 IL IL304728A patent/IL304728A/en unknown
- 2023-07-27 DO DO2023000145A patent/DOP2023000145A/es unknown
- 2023-07-27 EC ECSENADI202357264A patent/ECSP23057264A/es unknown
- 2023-07-27 CL CL2023002223A patent/CL2023002223A1/es unknown
- 2023-07-27 CO CONC2023/0010023A patent/CO2023010023A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022214618A1 (en) | 2023-08-17 |
| PE20240050A1 (es) | 2024-01-09 |
| CR20230362A (es) | 2023-11-23 |
| CO2023010023A2 (es) | 2023-09-08 |
| TW202239402A (zh) | 2022-10-16 |
| JP2024505261A (ja) | 2024-02-05 |
| DOP2023000145A (es) | 2023-10-31 |
| CN117177744A (zh) | 2023-12-05 |
| US20230109076A1 (en) | 2023-04-06 |
| IL304728A (en) | 2023-09-01 |
| KR20230142745A (ko) | 2023-10-11 |
| ECSP23057264A (es) | 2023-09-29 |
| WO2022165513A1 (en) | 2022-08-04 |
| CA3208618A1 (en) | 2022-08-04 |
| EP4284365A1 (en) | 2023-12-06 |
| BR112023015210A2 (pt) | 2023-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| CO2022002759A2 (es) | Antagonistas de hpk1 y sus usos | |
| UY38221A (es) | Inhibidores de proteínas ras con g12c mutantes | |
| ECSP22011692A (es) | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2 | |
| CO2023010023A2 (es) | Inhibidores de cdk2 y métodos de uso de los mismos | |
| ECSP22087539A (es) | Inhibidores de kras tricíclicos fusionados | |
| ECSP22029193A (es) | Aminas bicíclicas como inhibidoras de la cdk2 | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| CO2019001212A2 (es) | Composiciones y métodos de inhibición del masp-3 para el tratamiento de diversas enfermedades y trastornos | |
| UY38403A (es) | Moduladores de la alfa-1 antitripsina | |
| BR112022016382A2 (pt) | Triptaminas específicas para o uso no tratamento de doenças do humor | |
| CO2023015484A2 (es) | Compuesto, composiciones y métodos para el tratamiento de trastornos | |
| DOP2022000194A (es) | Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa | |
| BR112022000328A2 (pt) | Inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias | |
| BR112016028814A2 (pt) | ?composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição de reações imunitárias ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, composto, um sal, um isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, de um sal, de um isômero, ou de uma mistura farmaceuticamente aceitável do mesmo? | |
| CO2021001219A2 (es) | Benzimidazoles sustituidos como inhibidores de pad4 | |
| UY38233A (es) | Agentes inhibidores para la tirosina cinasa de bruton | |
| CL2021001198A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| CL2022002402A1 (es) | Inhibidores del eif4e y sus usos | |
| CO2020007895A2 (es) | Inhibidores de histona acetiltransferasa de la familia myst | |
| CL2022000967A1 (es) | Composiciones y métodos para el tratamiento de enfermedades hepáticas | |
| CO2022000266A2 (es) | Inhibidores de enzimas | |
| BR112022009710A2 (pt) | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 | |
| CO2022011258A2 (es) | Pirazolo-pirimidinas sustituidas y usos de las mismas | |
| CL2022002589A1 (es) | Tratamiento de trastornos respiratorios |